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INTRODUCTION 
Researchers do not know if medications act the same in the spaceflight environment as they do on Earth. Aspects of 
the spaceflight environment (low gravity, radiation exposure, closed environment, stress) have been shown to alter 
human physiology. Some of these physiological changes could be expected to alter either pharmacokinetics (PK, 
how the body absorbs, distributes, metabolizes and excretes administered medications) or pharmacodynamics (PD, 
receptors or signaling systems that are the targets of medication action). Anecdotal data has suggested that, at least 
for certain medications or indications, inflight medication efficacy is poor. In order to prepare for exploration 
missions where speedy evacuation to Earth may not be a possibility, the likelihood of unexpected medication action 
must be determined. 
METHODS 
This protocol was approved by the JSC IRB. This study will include administration of an antibiotic medication, 
either alone or in combination with sleep aid. Both study medications are FDA-approved prescription drugs and 
available for use on the ISS. After (double-blind) drug administration, blood samples will be collected over a period 
of 8 hours. These samples will be analyzed for content of the administered drug(s) and their metabolites, and 
pharmacokinetic analyses conducted. At the same time points when blood samples are collected, several measures of 
sleep/wakefulness and cognitive performance will be collected, including actigraphy, electroencephalography, and 
the psychomotor vigilance test (with the Cognition [1] suite of tests at certain, key, time points). This protocol will 
be conducted on crewmember volunteers pre-flight, during flight (post FD42), and post-flight so that flight-ground 
comparisons can be made for each individual.  
 
RESULTS 
Results from the “Rx Metabolism” study will provide unique information on pharmacokinetics and 
pharmacodynamics  in a microgravity environment. This information will allow the medical community to provide 
crew members with the best possible treatment plans.  
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